{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-163496","form_type":"8-K","ticker":null,"cik":"0001580063","company_name":"BIORA THERAPEUTICS, INC.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.500010+00:00","generated_at":"2026-06-14T04:57:21.658049+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biora Therapeutics cures Nasdaq listing deficiency; stock to remain on Global Market","bullets":["Nasdaq confirmed Biora cured noncompliance with $50M total assets and $50M total revenue continued listing requirement.","The matter is closed; common stock remains listed on The Nasdaq Global Market.","Letter received June 8, 2023; no further action needed from Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-163496","json":"https://secwatch.observer/filing/0001193125-23-163496.json","markdown":"https://secwatch.observer/filing/0001193125-23-163496.md","text":"https://secwatch.observer/filing/0001193125-23-163496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580063/000119312523163496/0001193125-23-163496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580063/000119312523163496/d574823d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:57:21.658049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aee64630eecd7e663869957d0f6696491a113a73","claim":"BIORA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding other.","evidence_excerpt":"June 8, 2023, Biora Therapeutics, Inc. (the “ Company ”) received a letter (the “ Compliance Letter ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company’s previously announced noncompliance with the $50 million in total assets and $50 million in total revenue requirement for continued listing on The Nasdaq Global Market has been cured. Accordingly, the Compliance Letter provided that the matter has been closed with Nasdaq. The Company’s common stock will continue to be listed and traded on The Nasdaq Global Market. SIGNATUR","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1580063/000119312523163496/0001193125-23-163496-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}